Carcinoembryonic antigen (CEA) is not normally produced in significant quantities after birth
but is elevated in colorectal cancer. The aim of this review was to define the current role of …

Introduction Colorectal cancer is the fourth most common cancer in the UK. There remains a
need for improved risk stratification following curative resection. Circulating-tumour DNA …

Follow‐up strategies for patients treated for non‐metastatic colorectal cancer - Jeffery, M - 2019
| Cochrane Library Skip to Content Cookies Our site uses cookies to improve your experience …

Carcinoembryonic antigen (CEA) was first identified as colon cancer antigen in 1965. The
higher serum CEA level than that of healthy individuals led to its clinical application as a …

Purpose: ctDNA offers a promising, noninvasive approach to monitor therapeutic efficacy in
real-time. We explored whether the quantitative percent change in ctDNA early after therapy …

BACKGROUND Exosomes are microvesicles, measuring 30-100 nm in diameter. They are
widely distributed in body fluids, including blood, bile, urine and saliva. Cancer-derived …

Background Most cancer survivors receive follow‐up care after completion of treatment with
the primary aim of detecting recurrence. Traditional follow‐up consisting of fixed visits to a …

A majority of patients with metastatic colorectal cancer (mCRC) experience recurrence post
curative-intent surgery. The addition of adjuvant chemotherapy has shown to provide limited …

Although the established ELISA-based sensing platforms have many benefits, the
importance of cytokine and cancer biomarkers detection for point-of-care diagnostics has …

The influence of PVT1 and MALAT1 variants on colorectal cancer (CRC) susceptibility and
their impact on PVT1/miRNA-186/epithelial-mesenchymal transition (EMT) and …